Qu Biologics Inc.

14 enregistrements totalisant 9,204,151.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.

Intégrer ce graphique

Registre des lobbyistes — correspondance possible correspondance par nom

Une organisation portant ce nom figure dans 3 enregistrements de lobbying fédéral (0 actuellement actifs), entre 2020 et 2020.

781242-367111-2 — Summa Strategies Canada 768275-367104-1 — Summa Strategies Canada Inc. 781242-367111-1 — Summa Strategies Canada

Correspondance automatique par nom d'organisation; une autre organisation du même nom est possible. Le Registre des lobbyistes fait foi. Le lobbying est légal et encadré — ceci est du contexte, pas une allégation.

Par ministère

Conseil national de recherches Canada $9,204,151 14 enregistrements

Enregistrements

Qu Biologics Inc. $5,176,172.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2022-2023
Canada

This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immun...

Qu Biologics Inc. $2,780,109.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2020-2021
Canada

This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.

National Research Council Canada | Conseil national de recherches Canada
EF 2012-2013
Canada
National Research Council Canada | Conseil national de recherches Canada
EF 2009-2010
Canada
National Research Council Canada | Conseil national de recherches Canada
EF 2009-2010
Canada
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2018-2019
Canada

This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomod...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.

National Research Council Canada | Conseil national de recherches Canada
EF 2009-2010
Canada
National Research Council Canada | Conseil national de recherches Canada
Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.

National Research Council Canada | Conseil national de recherches Canada
EF 2014-2015
Canada
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2020-2021
Canada

Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specifi...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.

National Research Council Canada | Conseil national de recherches Canada
EF 2010-2011
Canada
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2024-2025
Canada

The Project will support development of intellectual property capacity within the Firm.